← All trials
NCT05128916
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Jun 1, 2022
- Completion date
- Sep 1, 2022
- First posted
- Nov 22, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sohag UniversityLead sponsor
- Sohag UniversityReponsible party - principal investigator
- Sohag UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.